Document and Entity Information [Abstract] Document Type Document Quarterly Report Document Period End Date Document Fiscal Year Focus Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address State Or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Period Focus Amendment Flag Condensed Consolidated Balance Sheets Statement [Table] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Marketable Securities, Current Marketable securities, available for sale Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Other Assets, Noncurrent Other non-current assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities [Abstract] Liabilities Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total accrued expenses Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Non-current liabilities: Long-term Debt, Excluding Current Maturities Long-term debt, net of discount Amount of restricted stock repurchase liability as on the balance sheet date. Restricted Stock Repurchase Liability Restricted stock repurchase liability Liability from the early exercise Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (see note 12) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2022 and December 31, 2021; no shares issued or outstanding as of September 30, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Common stock, $0.0001 par value; 500,000,000 shares authorized as of September 30, 2022 and December 31, 2021, respectively; 23,308,685 and 23,225,637 issued as of September 30, 2022 and December 31, 2021, respectively; 23,300,796 and 23,205,915 outstanding as of September 30, 2022 and December 31, 2021, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Treasury Stock, Common, Value Treasury stock; 23,868 shares as of September 30, 2022; at cost Treasury stock, common, value Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Stockholders equity, Ending balance Stockholders equity, Beginning balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Treasury Stock, Common, Shares Treasury stock, common (in shares) Condensed Consolidated Statements of Operations Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Other Nonoperating Income (Expense) Other income (expense), net Net Income (Loss) Attributable to Parent Net loss Net loss Net loss Earnings Per Share, Basic Net loss per share, basic (in dollars per share) Earnings Per Share, Diluted Net loss per share, diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding, basic (in shares) Weighted average common stock outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares outstanding, diluted (in shares) Weighted average common stock outstanding, diluted (in shares) Condensed Consolidated Statements of Comprehensive Loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive gain (loss): Other Comprehensive Loss, Held-to-maturity Security, OTTI, after Tax and Adjustments, Attributable to Parent Unrealized gain (loss) on marketable securities Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Total other comprehensive gain (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity Class of Stock [Axis] Class of Stock [Domain] Represents information pertaining Series A convertible preferred stock. Series A Convertible Preferred Stock Represents information pertaining Series B convertible preferred stock. Series B Convertible Preferred Stock Equity Components [Axis] Equity Component [Domain] Preferred Stock Common Stock Additional Paid-in Capital Treasury Stock, Common [Member] Treasury Stock, Common Accumulated Other Comprehensive Loss Accumulated Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Shares, Outstanding Stockholders equity, Ending balance (in shares) Stockholders equity, Beginning balance (in shares) Stock Issued During Period, Value, Restricted Stock Award, Gross Vesting of restricted common stock Stock Issued During Period, Shares, Restricted Stock Award, Gross Vesting of restricted common stock (in shares) Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon stock option exercises Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Issuance of common stock upon stock option exercises (in shares) APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock-based compensation Stock Issued During Period, Value, New Issues Issuance of initial public offering common stock, net Stock Issued During Period, Shares, New Issues Issuance of initial public offering common stock, net (in shares) Stock Repurchased During Period, Value Common stock repurchase Stock Repurchased During Period, Shares Common stock repurchase (in shares) Adjustments to Additional Paid in Capital, Warrant Issued Warrant issuance The amount of stock issuance costs relating to temporary equity recognized during the period. Temporary Equity, Stock Issuance Costs Issuance costs Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Reconciliation of net loss to net cash used in operating activities: Share-based Payment Arrangement, Noncash Expense Stock-based compensation Paid-in-Kind Interest Non-cash interest expense Accretion (Amortization) of Discounts and Premiums, Investments Accretion of premium and interest on marketable securities Depreciation Depreciation expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Marketable Securities Purchase of marketable securities Proceeds from Sale and Maturity of Marketable Securities Proceeds from sales and maturities of marketable securities Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities Proceeds from Issuance of Common Stock Proceeds from issuance of common stock upon initial public offering, net of issuance costs Gross proceeds Proceeds from Issuance of Long-term Debt Proceeds from issuance of long-term debt Payments of Debt Issuance Costs Payment of debt issuance cost Payments of Stock Issuance Costs Cash paid for issuance costs of convertible preferred stock Proceeds from Stock Options Exercised Proceeds from issuance of common stock upon stock option exercises Payments for Repurchase of Common Stock Common stock repurchase Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (Decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information Interest Paid, Excluding Capitalized Interest, Operating Activities Interest paid Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of non-cash financing activities Conversion of Stock, Amount Issued Conversion of convertible preferred stock upon IPO Nature of Business Nature of Operations [Text Block] Nature of Business Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Presentation and Significant Accounting Policies Fair Value Measurements of Financial Assets Fair Value Disclosures [Text Block] Fair Value Measurements of Financial Assets Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Marketable Securities Accrued Expenses The entire disclosure of information pertaining to accrued liabilities classified as current. Accrued Liabilities Disclosure [Text Block] Accrued Expenses Convertible Preferred Stock The entire disclosure of information pertaining to temporary equity. Temporary Equity Disclosure [Text Block] Convertible Preferred Stock Debt Debt Disclosure [Text Block] Debt Warrant The entire disclosure for warrants. Warrants Note Disclosure [Text Block] Warrant Equity Stockholders' Equity Note Disclosure [Text Block] Equity Stock-Based Compensation Share-based Payment Arrangement [Text Block] Stock-Based Compensation Asset Purchase and License Agreements Asset Acquisition [Text Block] Asset Purchase and License Agreements Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Net Loss Per Share Earnings Per Share [Text Block] Net Loss Per Share Basis of Accounting, Policy [Policy Text Block] Basis of presentation of unaudited interim consolidated financial statements Consolidation, Policy [Policy Text Block] Principles of Consolidation Use of Estimates, Policy [Policy Text Block] Use of estimates Deferred Charges, Policy [Policy Text Block] Deferred offering costs Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of credit risk and significant suppliers Fair Value Measurement, Policy [Policy Text Block] Fair value measurements Marketable Securities, Policy [Policy Text Block] Marketable Securities, Available for Sale Comprehensive Income, Policy [Policy Text Block] Comprehensive Income (Loss) Legal Costs, Policy [Policy Text Block] Patent costs New Accounting Pronouncements, Policy [Policy Text Block] Recently adopted accounting pronouncements Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of fair value measurements of financial assets Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Schedule of marketable securities Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Schedule of Debt [Table Text Block] Schedule of long term debt and unamortized discount balances Tabular disclosure of interest expense on debt. Schedule of Interest Expense, Debt [Table Text Block] Schedule of interest expense Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of future principal payments Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of warrant outstanding Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block] Schedule of fair value assumptions Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of stock-based compensation expense Share-based Payment Arrangement, Option, Activity [Table Text Block] Summary of stock option activity Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions used in estimation of fair value Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Summary of restricted stock units activity Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of computation of basic and diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of antidilutive securities excluded from computation of diluted net loss per share Concentration Risk [Table] Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Accounts payable Research and development Supplier [Axis] Supplier [Domain] Represents number of suppliers member. Major suppliers Concentration Risk Type [Axis] Concentration Risk Type [Domain] Supplier Concentration Risk Concentration Risk [Line Items] Summary of significant accounting policies Represents the number of major vendors. Number Of Major Vendors Number of vendors Concentration Risk, Percentage Concentration risk Legal Fees Legal and professional costs Debt Securities, Available-for-sale [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Recurring Financial Instrument [Axis] Financial Instruments [Domain] Asset-backed securities Corporate Debt Securities Commercial Paper U.S. Government Debt Securities Money Market Funds Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Level 1 Level 2 Debt Securities, Available-for-sale [Line Items] Fair value measurements of financial assets Marketable Securities. Marketable Securities Cash and Cash Equivalents, Fair Value Disclosure Cash Equivalents Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Transfers from Level 1 to Level 2, Assets Fair Value, Assets, Level 2 to Level 1 Transfers, Amount Transfers from Level 2 to Level 1, Assets Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net Transfers into (out of) Level 3, Assets Marketable Securities [Table] Marketable Securities [Line Items] Marketable Securities Debt Securities, Available-for-sale, Amortized Cost Amortized Cost Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Unrealized losses Debt Securities, Available-for-sale Fair value Carrying value as of the balance sheet date of obligations incurred through that date and payable for preclinical and clinical costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Preclinical and Clinical Trial Costs, Current Accrued preclinical and clinical trial costs Carrying value as of the balance sheet date of obligations incurred through that date and payable for compensation for employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Compensation, Current Accrued compensation Carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting services. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Consulting Fees, Current Accrued consulting Accrued Professional Fees, Current Accrued professional services Other Accrued Liabilities, Current Accrued other Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents information pertaining to term loan. Term Loan [Member] Term loan Represents information pertaining to term loan tranche one. Term Loan Tranche One [Member] Term loan tranche one Represents information pertaining to term loan tranche two. Term Loan Tranche Two [Member] Term loan tranche two Counterparty Name [Axis] Counterparty Name [Domain] Represents information pertaining to K2 HealthVentures LLC. K2 HealthVentures LLC [Member] K2 HealthVentures LLC Minimum Scenario [Axis] Scenario [Domain] Represents information pertaining to debt repayment in first year after funding. Scenario, Debt Repayment in First Year After Funding [Member] Repayment in first year after funding Represents information pertaining to debt repayment in second year after funding. Scenario, Debt Repayment in Second Year After Funding [Member] Repayment in second year after funding Represents information pertaining to debt repayment in third year after funding. Scenario, Debt Repayment in Third Year After Funding [Member] Repayment in third year after funding Represents information pertaining to debt repayment after third year of funding. Scenario, Debt Repayment, After Third Year of Funding [Member] Repayment after third year of funding Debt Instrument [Line Items] Debt Debt Instrument, Face Amount Principal amount Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Period of interest only payments of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Debt Instrument, Interest Only Payments Term Interest only payments term Period of interest and principal payments of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Debt Instrument, Interest and Principal Payments, Term Period of interest and principal payments The percent of threshold interest rate for calculating effective interest rate. Debt Instrument, Threshold Interest Rate Threshold interest rate The percent of end of term charge of debt. Debt Instrument, End of Term Charge, Percent End of term charge (as a percent) Debt Instrument, Interest Rate, Effective Percentage Effective interest rate The percent of prepayment premium on a debt instrument. Debt Instrument, Prepayment Premium, Percent Percent of prepayment premium Debt Conversion, Original Debt, Amount Principal amount for debt conversion Debt Instrument, Convertible, Conversion Price Conversion price The percentage of Nasdaq beneficial ownership limitations. Nasdaq Beneficial Ownership Limitations, Percentage Nasdaq beneficial ownership limitations, percentage The amount of investments the lenders may invest in future equity financings. Future Equity Financing, Investment from Lenders Investment from lenders in future equity financings Percent of equity investment from lenders as percent of total amount raised in financing. Equity Financing, Investment from Lenders, As Percent of Total Amount Raised in Financing Percent of equity investment from lenders The amount of cash, cash equivalents and marketable securities balances to be maintained as per debt covenant. Debt Instrument Covenant, Cash, Cash Equivalents and Marketable Securities Balance to be Maintained Cash, cash equivalents and marketable securities balances to be maintained The amount of total market capitalization. Total Market Capitalization Total market capitalization Debt Issuance Costs, Net Debt issuance costs Interest Expense, Debt Interest expense Interest expense Long-term Debt, Gross Outstanding principal amount Amount of accreted liability for final payment fee of debt. Debt Instrument, Accreted Liability for Final Payment Fee Add: accreted liability of final payment fee Debt Instrument, Unamortized Discount, Noncurrent Less: unamortized debt discount, long term Long-term Debt, Current Maturities Less: current portion of long-term debt - principal Interest Expense, Debt [Abstract] Components of interest expense Interest Expense, Debt, Excluding Amortization Interest Paid or Accrued Amortization of Debt Discount (Premium) Non-Cash amortization of Debt discount (Including Warrants) Amount of non cash accrued back end fee related to debt. Non Cash Accrued Back End Fee Non-Cash accrued Back-end fee Maturities of Long-term Debt [Abstract] Future principal payments schedule Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months 2023 Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two 2024 Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three 2025 Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four 2026 Long-term Debt Total Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of shares purchased by warrants Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants exercise price Class of Warrant or Right, Outstanding Warrant outstanding Fair Value Measurement Inputs and Valuation Techniques [Table] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input, Share Price [Member] Stock price Measurement Input, Exercise Price [Member] Strike price Measurement Input, Price Volatility [Member] Volatility (annual) Measurement Input, Risk Free Interest Rate [Member] Risk-free rate Measurement Input, Expected Term [Member] Estimated time to expiration (years) Measurement Input, Expected Dividend Rate [Member] Dividend yield Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrant Fair value of warrants outstanding. Warrants, Fair Value Disclosure Fair value of warrants Warrants and Rights Outstanding, Measurement Input Warrants, measurement input Schedule of Stock by Class [Table] Represents information pertaining to Cowen and Company, LLC. Cowen and Company, LLC [Member] Cowen and Company, LLC Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to At-The-Market offering. At The Market Offering [Member] At-The-Market offering Class of Stock [Line Items] Equity Represents the number of votes that each holder of the common stock is entitled to cast. Common Stock, Number Of Votes Per Share Number of votes per common stock Common Stock, Dividends, Per Share, Declared Dividends declared Common Stock, Dividends, Per Share, Cash Paid Dividends paid Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location [Axis] Income Statement Location [Domain] General and administrative Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock-based compensation Share-based Payment Arrangement, Expense Stock-based compensation expense included in operating expenses Stock-based compensation expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Represents information pertaining to the 2021 Equity Incentive Plan. 2021 Equity Incentive Plan Represents information pertaining to the 2021 Employee Stock Purchase Plan (ESPP). 2021 Employee Stock Purchase Plan Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Shares available for issuance Number of additional shares authorized for issuance under share-based payment arrangement, as a percentage of total outstanding shares. Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Aggregate Shares Outstanding Additional number of shares authorized (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Additional number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at end of period (in shares) Outstanding at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Vested at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested and expected to vest at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at end of period (in dollars per share) Outstanding at beginning of period (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Cancelled (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Vested at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested and expected to vest at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted-average remaining contractual term and Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding at end of period (in years) Weighted average remaining contractual term for option awards vested, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Remaining Contractual Term Vested at end of period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Vested and expected to vest at end of period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Outstanding at end of period (in dollars) Outstanding at beginning of period (in dollars) The aggregate intrinsic value of options granted. Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Aggregate Intrinsic Value Granted (in dollars) The aggregate intrinsic value of options vested. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Intrinsic Value Vested at end of period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Vested and expected to vest at end of period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant-date fair value of stock options granted Award Type [Axis] Award Type [Domain] Outstanding stock options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Fair value assumptions Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Volatility, Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Volatility, Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Fair value of options vested Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Expected remaining weighted-average period for recognition Represents the early exercise of employee options becoming subject to restricted stock agreements. Early exercise of employee options Restricted Stock Units Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Number of shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Unvested at end of period (in shares) Unvested at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted-average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Unvested at end of period (in dollars per share) Unvested at beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Asset Acquisition [Table] Asset Acquisition [Axis] Asset Acquisition [Domain] Represents information pertaining to asset purchase agreement relating to seribantumab, a fully humanized immunoglobulin G2 monoclonal antibody against HER3. Asset Purchase Agreement relating to Seribantumab Represents information pertaining to Dyax agreement. Dyax Represents information pertaining to Selexis agreement. Selexis Represents information pertaining to U.S. Department of Health and Human Services agreement. National Institute of Health Asset Acquisition [Line Items] Asset Acquisition, Consideration Transferred Upfront payment The amount of development, regulatory and sales milestone payments payable under the collaboration and license agreements. Collaboration And License Agreements, Milestone Payments Payable Milestone payments payable The number days of prior written notice to terminate the agreement. Collaboration And License Agreements, Notice Period Number of days written prior notice to terminate agreement The amount of development, regulatory and sales milestone payments payable under the collaboration and license agreements for per licensed product. Collaboration And License Agreements, Milestone Payments Payable, Per Licensed Product Milestone payments payable, per licensed product The amount of royalty payments payable under the collaboration and license agreements. Collaboration And License Agreements, Royalty Payments Payable Royalty payments payable Percentage of royalty on net sales of licensed products under the collaboration and license agreement. Collaboration And License Agreements, Percentage Of Royalty On Net Sales Of Licensed Products Percentage of royalty on net sales of licensed products The amount of development, regulatory and sales milestone payments paid under the collaboration and license agreements. Collaboration And License Agreements, Milestone Payments Paid Milestone payments paid Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents information pertaining to license agreement. License Agreement [Member] License Agreement Represents information pertaining to CSPC Megalith Biopharmaceutical Co., Ltd. CSPC Megalith Biopharmaceutical Co., Ltd [Member] CSPC Megalith Biopharmaceutical Co., Ltd Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Other Research Arrangements The amount of upfront license fee payable under the collaboration agreement. Collaboration Agreement, Upfront License Fee Upfront license fee Term of the collaboration agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Collaboration Agreement, Term Term of agreement (in years) The amount of development and regulatory milestone payments under the collaboration agreement. Collaboration Agreement, Development and Regulatory Milestone Payments Development and regulatory milestone payments The amount of commercial milestone payments under the collaboration agreement. Collaboration Agreement, Commercial Milestone Payments Commercial milestone payments The amount payable as percentage of non royalty sublease income. Collaboration Agreements, Payments as Percentage of Non Royalty Sublease Income Payments as percentage of non-royalty sublicense income Caris Agreement Represents information pertaining to Caris Life Sciences. Caris The amount of upfront or milestone payments or royalties due to either party under the collaboration agreement. Collaboration Agreement, Payments Due Upfront or milestone payment Renewal term of the collaboration agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Collaboration Agreement, Renewal Term Renewal term (in years) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Unvested restricted stock Warrant. Warrant Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation (in shares)